Introduction {#sec1}
============

In previous studies, we described *N*-benzyl-substituted tetrahydroisoquinoline (THIQ) derivatives as novel microtubule disruptors with potential therapeutic application for the treatment of cancer.^[@ref1]−[@ref5]^ These compounds were designed to mimic the 2-substituted estratriene class of microtubule disruptors derived from the endogenous steroid 2-methoxyestradiol (2ME) and, in particular, its sulfamate derivatives (e.g., **2a** (STX140), [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref6]−[@ref10]^ Incorporation of a phenolic 3-*O*-sulfamate group is generally observed to be highly beneficial for both activity and oral bioavailability, and STX140 is an optimized anticancer agent with both 3-*O*- and 17-*O*-sulfamate groups.^[@ref11]^ Agents possessing such sulfamate esters have reached multiple clinical trials in oncology and elsewhere, primarily for hormone-dependent diseases.^[@ref11],[@ref12]^ The sulfamoyl group can serve in diverse roles.^[@ref12]^

![Design of dichlorobenzyl-substituted THIQ-based microtubule disruptors **7** and **8**.](ao-2018-02879u_0001){#fig1}

STX140 was developed primarily for hormone-independent cancer applications, and the nonsteroidal THIQ core was used as a mimic of the steroidal AB-ring system from which steroidomimetics were constructed. Such compounds have markedly better physicochemical properties than 2ME and even STX140 but can maintain in vivo potency. Substitution of the THIQ nucleus at C6 and C7, with those groups requisite for activity in the steroidal series, was thus desirable. Attachment at N2 of a group projecting into the area of space occupied by the steroidal D-ring and bearing an H-bond acceptor known to be required for optimal activity completed the prototypical steroidomimetic design.^[@ref1],[@ref2],[@ref11]^ Further optimization led to THIQs methylated at C3 forcing a more favorable conformation of the steroidal D-ring mimic by steric repulsion (THIQs of type **3** and **4**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref3]^ Related THIQ core chimeric microtubule disruptors possessing the trimethoxy aryl motif common to many tubulin colchicine site binders were designed and then further optimized.^[@ref4],[@ref5]^ As a result, the best compounds in both series displayed nanomolar in vitro activities, making them equipotent or better than the steroidal derivatives that underpinned their design.^[@ref3]−[@ref5]^ Most recently, we designed another steroidal AB-ring mimic by using a dihydroquinazolinone (DHQ) core structure.^[@ref13]^ The most potent DHQs derived from this series were also sulfamates of type **6** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) with the best compounds again displaying nanomolar in vitro activities.

Like the steroids, the most potent heterocyclic derivatives were found to disrupt the polymerization of tubulin and inhibit the binding of \[^3^H\]colchicine to tubulin. THIQ sulfamates also inhibit carbonic anhydrases (CA) II,^[@ref4]^ an interaction believed to contribute to the high oral bioavailability observed for the steroid derivatives,^[@ref14],[@ref15]^ and CAIX,^[@ref16]^ which affords extra targeting of hypoxic tumors. In addition, the activity of nonsteroidal THIQ derivatives mirrors that of the steroidal series, with compounds capable of inhibiting the growth of taxane-resistant cancer cells^[@ref17]−[@ref19]^ and human umbilical vein endothelial cell proliferation (a commonly used marker for antiangiogenic activity),^[@ref20],[@ref21]^ thus supporting the idea that these small-molecule agents work in a similar manner to 2ME and its bis-*O*-sulfamate derivative **2a** (STX140).

Very recently, the mechanism of these heterocyclic sulfamate esters in the destabilization process of microtubule polymerization was investigated for the first time in atomic detail. The crystal structure of the most potent DHQ sulfamate of type **6**, the *N*-(2′,5′-dimethoxybenzyl) derivative **6a**, in complex with tubulin revealed molecular details to support further strategies for structure-based optimization. Interestingly, the sulfamate group was shown to play a role in binding at the colchicine site of tubulin. The mechanism of microtubule destabilization, at least for this particular DHQ **6a**, was established as preventing the curved-to-straight tubulin conformational transition required for microtubule formation.^[@ref13],[@ref22]^

DHQ derivatives, although highly effective, are not charged at the linking N-atom. THIQ derivatives likely have more developmental potential, their charged nature in particular affording better solubility via salt formation at the N2 position. Moreover, they have been shown to be orally active in vivo when dosed in an aqueous buffer, with some being as potent as STX140.^[@ref4]^ It was thus of interest to explore the potential for further optimization of such derivatives via new substitutions in the pendant aryl ring and, moreover, if this THIQ class could also be cocrystallized with the αβ-tubulin heterodimer, such that atomic level information could be obtained, for further structure--activity relationship (SAR) development. In the present work, we explore the replacement of methoxy groups present in the steroidal D-ring mimic of C3-methylated THIQs with chloro substituents to determine whether such less polar and more lipophilic H-bond acceptors improve microtubule disruptor potency ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Therefore, we introduced 2′,3′-, 2′,4′-, and 2′,5′-dichlorobenzyl groups at N2 to explore SAR in a focused series of phenols and their sulfamate esters and explored their antiproliferative and antitubulin activities.

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

The candidate THIQs were synthesized in two steps starting from (±)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-THIQ **9**.^[@ref3]^*N*-Benzylation using dichlorobenzyl halides, diisopropylethylamine (DIPEA) in *N*,*N*-dimethylformamide (DMF) at 140 °C for 18 h gave phenols **7a--c** in moderate yields. The target sulfamates **8a--c** were synthesized using sulfamoyl chloride as a solution in *N*,*N*-dimethylacetamide (DMA)^[@ref23]^ ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Dichloro-tetrahydroisoquinoline-Based Microtubule Disruptors\
Reagents and conditions: (i) ArCH~2~X (X = Cl or Br), NaBr (for X = Cl), DIPEA, DMF, 140 °C, 18 h; (ii) H~2~NSO~2~Cl, DMA, rt.](ao-2018-02879u_0007){#sch1}

Biology {#sec2.2}
-------

All six compounds were evaluated at the US National Cancer Institute (NCI) in the full 60-cell-line assay that allows activity across a wide range of cancer types to be assessed ([Tables [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [2](#tbl2){ref-type="other"}). The in vitro activities of these compounds against DU-145 prostate and MDA MB-231 breast cancer cell line proliferation are shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Data from both cell lines are in strong agreement. Overall, compounds in this small series of N2-dichlorobenzyl C3-methyl-substituted THIQs exhibit activities in the micromolar and nanomolar ranges. Phenols **7b--c** are only about 3--5-fold less active than their corresponding sulfamates **8b--c** against the proliferation of DU-145 prostate cancer cells and MDA MB-231 breast cancer cells. The exception is phenol **7a** that proved to be more than 10-fold less active than its corresponding sulfamate, **8a**. GI~50~ values of the sulfamates **8a--c** range between 90 nM (**8c**; DU-145) and 551 nM (**8a**; MDA MB-231). The best THIQ **8c** of this small SAR screening set proved slightly more potent or very similar to previously reported THIQs, **4a--b**.^[@ref3]^ However, data from the NCI-60-cell-line panel for **4a--b** against DU-145 and MDA-MB 231 cells suggested that **8c** is significantly more potent than **4a**, but only about as potent as **4b**. Overall, the antiproliferative activity was significantly improved when the 2′-methoxy group was replaced with a 2′-chloro substituent. However, no further enhancement was observed when the 5′-methoxy group too was replaced with a 5′-chloro substituent. As these (±)-C3 methyl-substituted THIQs adopt a steroid-like conformation with the substituent at C5′ pointing into the same area of space as the steroidal C17 β-hydroxyl group,^[@ref1]−[@ref3]^ it seems likely that the substituent at C2′ will sterically interact with the two hydrogens at C1. Therefore, only relatively small one-atom substituents such as chlorine seem well tolerated at the C2′ position. Note that the hydrogen and fluoro substituents at C2′ in combination with a C5′ methoxy group were also very well tolerated.^[@ref3]^ It seems that the only marginally larger C2′ methoxy group could already force too much of an angle between the THIQ B-ring and the pendant N2-benzyl ring, resulting in a less favorable overall conformation, leading to a decrease in activity (**4a**; MDA MB-231: 2.1 μM). However, there seem to be less restrictions for the second H-bond acceptor at C5′ and more space might be available around that binding site. Note, of course, that in all cases here, the activities of racemic mixtures are being compared, with all usual caveats, but vide infra for further discussion on this point.

###### Antiproliferative Activity of Racemic THIQ Derivatives Against DU-145 Human Prostate and MDA MB-231 Human Breast Cancer Cells in Vitro from the NCI-60 Cell Line Panel[a](#t1fn1){ref-type="table-fn"}

                                              GI~50~ (μM)                             
  -------- ------------ ----- ---- ---- ----- --------------------------------------- --------------------------------------
  **4a**   SO~2~NH~2~   OMe   H    H    OMe   0.371                                   2.1
                                              0.189[b](#t1fn2){ref-type="table-fn"}   0.16[b](#t1fn2){ref-type="table-fn"}
  **4b**   SO~2~NH~2~   Cl    H    H    OMe   0.085                                   0.299
                                              0.4[b](#t1fn2){ref-type="table-fn"}     0.4[b](#t1fn2){ref-type="table-fn"}
  **7a**   H            Cl    Cl   H    H     4.18                                    7.05
  **8a**   SO~2~NH~2~   Cl    Cl   H    H     0.301                                   0.551
  **7b**   H            Cl    H    Cl   H     0.261                                   0.465
  **8b**   SO~2~NH~2~   Cl    H    Cl   H     0.195                                   0.365
  **7c**   H            Cl    H    H    Cl    0.241                                   0.542
  **8c**   SO~2~NH~2~   Cl    H    H    Cl    0.090                                   0.324

GI~50~ figures represent mean values from triplicate experiments. All compounds of type **4**, **7**, and **8** are racemic mixtures.

GI~50~ values for **4a--b** are additionally taken from the literature.^[@ref3]^

###### Antiproliferative Activity of *N*-Dichlorobenzyl-Substituted THIQs against Various Other Cancer Cell Lines in Vitro from the NCI-60 Cell Line Panel[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

  GI~50~ (μM)                                                   
  ------------- ------- ------- ------- ------- ------- ------- -------
  **4a**        0.504   0.446   0.331   0.584   0.298   1.64    0.562
  **4b**        0.075   0.048   0.042   0.069   0.039   0.372   0.102
  **7a**        3.69    4.61    4.39    4.37    2.64    5.83    5.01
  **8a**        0.387   0.226   0.227   0.119   0.137   0.933   0.316
  **7b**        0.427   0.34    0.235   0.596   0.201   0.668   0.457
  **8b**        0.183   0.054   0.106   0.050   0.045   0.657   0.151
  **7c**        0.33    0.26    0.132   0.448   0.17    0.706   0.324
  **8c**        0.055   0.073   0.046   0.056   0.026   0.345   0.129

GI~50~ figures are mean values from triplicate experiments. All compounds of type **4**,**7**, and **8** are racemic mixtures. MGM represents the mean concentration that caused 50% growth inhibition in all 60 cell lines.

GI~50~ values for **4a--b** are taken from the literature.^[@ref3]^

Additionally, data from six more tumor cell lines are presented along with the mean activity across the whole panel (MGM value; [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The trend that emerged for these THIQ derivatives against the proliferation of DU-145 prostate cancer cells and MDA MB-231 breast cancer cells in vitro was essentially confirmed across the whole NCI 60-cell-line assay. It also confirms the potential of these *N*-dichlorobenzyl compounds against a broad range of cancer phenotypes with **8c**, in particular, proving highly active (e.g., 26 nM in OVCAR-3; MGM = 129 nM). Over the whole 60-cell-line panel, compound **4b** was slightly more potent (MGM = 102 nM; [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Additionally, the trend mentioned above with regard to **4a--b** and **8c** seems to hold well. Overall **4b** and **8c** were about 4--5 times more potent than **4a**.

To confirm the target for these, we established the activity of the sulfamoylated compounds, **8a--c** as microtubule disruptors, alongside the established potent clinical microtubule disruptor, combretastatin A-4 (**CA-4**), initially in tubulin polymerization assays and alongside the previously reported THIQ sulfamate, **10**([@ref5]) ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Gratifyingly, the 2′,5′-dichlorobenzyl derivative **8c** very effectively inhibited the assembly of tubulin, with an IC~50~ of 0.98 μM, being only about 2-fold less potent than **CA-4**. The IC~50~ in these tubulin-based assays, as is typical with antitubulin agents with potent cytotoxic activity, far exceeds the antiproliferative GI~50~ dose, at least in part because the GI~50~ values refer to the concentration in the media, not in the cells. Inhibition of colchicine binding to tubulin for these compounds was also determined relative to **CA-4** for further proof of targeting, with **8c** being the overall best THIQ derivative to date showing 67% inhibition at 5 μM ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). It is reasonable to propose that these novel THIQs can, at least partially, be assumed to disrupt normal dynamic tubulin polymerization by interacting at the colchicine site. Also, this provides further evidence that methoxy groups as polar H-bond acceptors are not an essential requirement in the D-ring mimic. Overall, the tubulin assays showed a striking difference in potency between compounds with methoxy and chloro as the C2′ substituents (**4a** vs **4b**), whereas the difference in potency is much smaller when these substituents are positioned at C5′ (**4b** vs **8c**). But also, here, the C5′ chloro compound **8c** displayed an improved IC~50~ and inhibition of colchicine binding than the corresponding C5′ methoxy compound, **4b**.

###### Activity of *N*-Dichlorobenzyl-Substituted THIQs as Tubulin Polymerization Inhibitors and \[^3^H\]Colchicine Binding (5 μM Inhibitor) to Tubulin[a](#t3fn1){ref-type="table-fn"}

             tubulin assembly   colchicine binding
  ---------- ------------------ --------------------
  **CA-4**   0.54 ± 0.06        98 ± 0.1
  **4a**     \>20               8.2 ± 2
  **4b**     1.7 ± 0.2          55 ± 5
  **8a**     2.1 ± 0.2          35 ± 1
  **8b**     1.4 ± 0.2          47 ± 2
  **8c**     0.98 ± 0.06        67 ± 2
  **10**     1.3 ± 0.01         49 ± 3

Values are the mean ± SD of at least two determinations. All compounds of type **4** and **8** are racemic mixtures.

Data for **4a** are taken from the literature.^[@ref3]^

As in previously published work on DHQs,^[@ref13]^ we employed X-ray crystallography to determine the atomic level binding mode of a THIQ derivative within the αβ-tubulin heterodimer ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). To avoid complications that would arise from using the racemic sulfamate, **8c**, we chose a highly potent nonracemic THIQ, \[2-(3′-bromo-4′,5′-dimethoxybenzyl)-7-methoxy-6-sulfamoyloxy-1,2,3,4-THIQ---STX3451, **10**\], without the C3-methyl group chiral center that had been optimized earlier^[@ref5]^ and which is not too dissimilar to **8c** in its antitubulin activities ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). STX3451 exerts antiproliferative and antimitotic effects, inducing apoptosis and involving autophagic processes in MDA-MB-231 metastatic breast and A549 epithelial lung carcinoma cells^[@ref24]^ and also induces cell death effectively in NF1 tumor cell lines.^[@ref25]^ It is therefore somewhat more attractive as a potential development candidate than **8c**. Compound **10** was soaked into crystals formed by a protein complex composed of two αβ-tubulin heterodimers, the stathmin-like protein RB3 and tubulin tyrosine ligase (termed T~2~R-TTL),^[@ref26]^ and we solved the T~2~R-TTL-**10** complex structure using X-ray crystallography to 2.4 Å resolution ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}B, **4A**; [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}) (PDB ID 6HX8). STX3451 binds to the tubulin colchicine site^[@ref22]^ at the intradimer interface created by residues from the strands βS8 and βS9 the helix βH8 of β-tubulin, and the loop αT5 of α-tubulin ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). STX3451 is well accommodated within the binding site, displaying an extended "steroid-like" conformation. These data now provide the second cocrystal structure of an antitubulin agent that possesses a sulfamate group and the first one where the steroidal AB-ring system is mimicked by a THIQ core. [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B shows a comparison of the new THIQ sulfamate binding mode within the colchicine site with that of the earlier DHQ sulfamate **6a**.^[@ref13]^

![Overall view of the T~2~R-TTL-STX3451 complex structure. The α- and β-tubulin chains are in dark and light grey, respectively, TTL is in yellow/orange, and RB3 is in violet ribbon representation. The tubulin-bound STX3451 and the nonexchangeable guanosine 5′-triphosphate (GTP) molecules bound to α-tubulin are shown as sphere representations. The carbon atoms of STX3451 are colored in cyan.](ao-2018-02879u_0002){#fig2}

![Crystal structure of the complex of tubulin with STX3451. (A) Structures of **10** (STX3451), colchicine, and **11**. (B) STX3451 binding mode within the αβ-tubulin heterodimer. The α- and β-tubulin subunits are represented as dark and light gray ribbons, respectively. STX3451 carbon atoms and the nonexchangeable GTP molecule bound to α-tubulin are shown as cyan and orange spheres, respectively.](ao-2018-02879u_0003){#fig3}

![Detailed interaction of the tubulin-STX3451 complex. (A) Detailed view of the interaction network seen between STX3451 (aquamarine) and tubulin (gray). Residues of tubulin that interact are labeled and shown in stick representation. Oxygen and nitrogen atoms are colored red and blue, respectively, and carbon atoms are represented as aquamarine (STX3451) or gray (tubulin). Hydrogen bonds are shown as black dashed lines, and secondary structural elements of tubulin are labeled in blue. For simplicity, only α-tubulin residues and secondary structural elements are marked with an α. (B) Same close-up view as in (A) with the superimposed DHQ, **6a** (pale yellow; PDB ID 5OSK; root-mean-square deviation of 0.20 Å over 409 C~α~-atoms) structure. (C) Same close-up view as in (A) with the final 2mFo-DFc (blue) and mFo-DFc (green and red) electron density maps contoured at 1.0σ and ±3.0σ, respectively. The green electron density blob marked with an arrow suggests an alternate conformation of the 5′-methoxy group of the C-ring. (D) Sigma A-weighted mFo-DFc (light green mesh) simulated annealing electron-density omit map contoured at 3.0σ. The map was calculated excluding the atoms corresponding to STX3451 only. Both the STX3451 molecule (aquamarine sticks) and the two water molecules (red spheres, HOH) of the final refined structure are superimposed to highlight the quality of the map.](ao-2018-02879u_0004){#fig4}

###### Refinement Statistics of T~2~R-TTL-STX3451[a](#t4fn1){ref-type="table-fn"}

  **Data Collection**[a](#t4fn1){ref-type="table-fn"}   
  ----------------------------------------------------- ------------------------
  space group                                           *P*2~1~2~1~2~1~
  **Cell Dimensions**                                   
  *a*, *b*, *c* (Å)                                     104.0, 155.6, 180.9
  resolution (Å)                                        48.4--2.4 (2.46--2.40)
  *R*~merge~ (%)                                        9.3 (266.0)
  *R*~meas~ (%)                                         10.1 (288.9)
  *R*~pim~ (%)                                          4.2 (115.8)
  *I*/σ*I*                                              16.7 (0.8)
  CC~1/2~[b](#t4fn2){ref-type="table-fn"}               99.9 (29.4)
  completeness (%)                                      100 (100)
  redundancy                                            6.8 (6.6)

  **Refinement**                                                
  ------------------------------------------------------------- ------------
  resolution (Å)                                                48.4--2.4
  no. unique reflections                                        115 121
  *R*~work~/*R*~free~                                           19.5/24.0
  **No. Atoms**                                                 
  protein                                                       17 324
  ligand                                                        104
  *water*                                                       303
  **Average*B*-Factors(Å**^**2**^**)**                          
  protein                                                       91,3
  ligand (chain B/D)                                            66.3/114.3
  *water*                                                       74.3
  Wilson *B*-factor                                             63.9
  **R.m.s. Deviations**                                         
  bond lengths (Å)                                              0.002
  bond angles (deg)                                             0.535
  **Ramachandran Statistics**[c](#t4fn3){ref-type="table-fn"}   
  favored regions (%)                                           97.1
  allowed regions (%)                                           2.9
  outliers (%)                                                  0

Highest shell statistics are in parentheses.

CC~1/2~ = percentage of correlation between intensities from random half-datasets.^[@ref29]^

As defined by MolProbity.^[@ref30]^

The C-ring of STX3451 is buried into a hydrophobic pocket formed by the β-tubulin residues: βVal238, βCys241, βLeu242, βLeu255, βMet259, βAla316, βIle318, βAla354, βThr376, and βIle378 ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Moreover, the 4′-methoxy oxygen of the C-ring forms a water-mediated hydrogen bond to the main chain amide and carbonyls of βCys241, βGly237, and βVal238. The A-ring of STX3451 is stacked between the side chains of βAsn258 and βLys352, and further stabilization is provided by hydrogen bonds between the sulfamate moiety and the side chains of βLys352, βAsn349, and αSer178, the main chain amide of αVal181, and the main chain carbonyl group of βAsn349. Compared to the DHQ derivative **6a**([@ref13]) (PDB ID 5OSK), which possesses an amine group in the B-ring, no water-mediated interaction to the carbonyl groups of the side chain and main chain of αAsn101 and αThr179 is observed for STX3451 ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Moreover, the 3′-bromo substituent of the C-ring in STX3451 forms a water-mediated hydrogen bond to the main chain carbonyl of βVal238, a space that is otherwise occupied by the 2′-methoxy group in **6a** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B).

Recently, THIQ compound (±)-**11** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), which is the same as **10** but with an additional (±)-C3 methyl group as in the present **8c** compound series, was synthesized and evaluated.^[@ref5]^ As it was found to be similar to **10** (STX3451) in antitubulin assays (IC~50~ 2.4 μM, 50% inhibition of colchicine binding^[@ref5]^ vs IC~50~ 1.3 μM and 49%, respectively) ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, but note the very slightly different assay conditions), we would suggest that the additional (±)-C3 methyl group of the present series should, in principle, be well accommodated, as presumably also the 2′,5′-dichloroaryl motif. This former feature was not an issue in the DHQ **6a** instance (see [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B) because a planar carbonyl group occupies the C3 position. A closer inspection of the C3 environment in the tubulin-STX3451 crystal structure reveals that there may be enough space to accommodate both enantiomers of compound **11** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). However, we modeled compound **11** in both the (R)- and (S)-configurations into the STX3451 structure without energy minimization and inspected the C3 environment of both the enantiomers ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). The model suggests that the (S)-enantiomer likely binds without any structural rearrangements, whereas the (R)-enantiomer would clash into helix βH8, thereby requiring structural adaptations to get accommodated into the pocket or even preventing binding. For these reasons, we expect that administration of the racemate would preferentially select for the (S)-enantiomer binding to tubulin. It is tempting to view the respective antitubulin IC~50~ values of (±)-**11** and **10** in the light of this (2.4 and 1.3 μM) and speculate that (R)-**11** might be a very weak inhibitor or even totally inactive. The antitubulin activity of racemic 3-methyl-substituted THIQs, such as **8c**, may therefore actually be an underestimate if the (R)-enantiomer is not accommodated or only binds weakly in the colchicine site because of the structural adaptations necessary. Exploration of this possibility must however await the resolution of the isomers but, given the greater development potential of the achiral THIQ sulfamate **10**, this has not been pursued. Further development of these THIQs through medicinal chemistry might include the introduction of a (±)-C4 hydroxyl group as it could attract a water-mediated interaction to the carbonyl groups of the side chain and main chain of αAsn101 and αThr179, as was observed for DHIQ, **6a**.^[@ref13]^

![Molecular models of compound **11** in (A) (R)- and (B) (S)-configuration. Both enantiomers are shown in stick and semi-transparent surface representation. Carbon atoms are colored in red (A) and green (B). The tubulin backbone is in white and grey ribbon representation. Selected residue sidechains are in stick representation and are labeled. Secondary structural elements are labeled in blue. Chemical structures of compound **11** in (C) (R)- and (D) (S)-configuration.](ao-2018-02879u_0005){#fig5}

We further compared the binding mode of STX3451 **10** with that of colchicine by superimposition of both β-tubulin chains of their tubulin-ligand complexes ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}; PDB ID 4O2B; rmsd of 0.428 Å over 393 C~α~-atoms of chains B). Tubulin undergoes a "curved-to-straight" conformational change when polymerized into microtubules,^[@ref22],[@ref27]^ involving an overall compaction of the colchicine binding site through mainly the βT7 loop and βS8 strand of the β-tubulin chain.^[@ref22]^ As already observed for the DHQ derivative **6a**,^[@ref13]^ both compound poses show similarity and reveal that the respective A rings and associated methoxy groups of STX3451 and colchicine are very well superimposed, whereas the more flexible C ring of STX3451 is more extended. Both compounds, STX3451 and **6a**, share a unique and common polar interaction with the sulfamoyl group of the main chain of αVal181. As a result of the different shapes of the molecules (STX3451 vs colchicine), major conformational changes of both the αT5 and βT7 loops are observed ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). In summary, the results have established STX3451 **10** as a tubulin-binding ligand at the colchicine site in atomic detail. They also imply that **10**, similar to other colchicine-site ligands,^[@ref22],[@ref28]^ achieves microtubule destabilization mechanistically by preventing the curved-to-straight conformational transition.

![Superimposition of the tubulin-STX3451 (lime/grey) and the tubulin-colchicine (violet; PDB ID 4O2B) complex structure in the same orientation and representation as in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A. The structures were superimposed onto their β1-tubulin chains.](ao-2018-02879u_0006){#fig6}

Conclusions {#sec3}
===========

THIQ sulfamate-based microtubule disruptors have been further explored. Racemic N2-dichlorobenzyl C3-methyl-substituted THIQs showed excellent in vitro activities in the NCI-60-cell-line assays and antitubulin properties. Chlorine substitution for methoxy was found to be effective, and **8c** in particular exhibits antiproliferative activity in the 90 nM range, inhibiting tubulin assembly and interfering effectively with the colchicine site. To explore tubulin binding at the atomic level without the complication of chirality, a parent THIQ STX3451 **10** was cocrystallized successfully with the αβ-tubulin heterodimer. STX3451 binds more deeply in the colchicine site than colchicine itself, and the sulfamate group is involved in binding through specific interactions with β-tubulin residues beyond those accessed by colchicine. This is the first example of a THIQ derivative bearing a sulfamate ester bound to tubulin to be explored in such detail. With subtle differences, **10** adopts a broadly similar binding pose to a related DHQ derivative. Structural implications derived from the ligand are that C3 methyl group substitutions, as in the dichlorobenzyl derivatives, can be accommodated in the colchicine site. Modeling of (R)-**11** and (S)-**11** into the STX3451-tubulin structure further revealed that the (S)-enantiomer might be mainly responsible for the tubulin activity of such racemic C3 methyl-THIQ sulfamates as the C3 methyl group of the (R)-enantiomer would sterically clash with tubulin residues. Most likely, mechanistically microtubule destabilization by STX3451 is via prevention of the curved-to-straight conformational transition of tubulin, as shown for colchicine and the STX3451-related quinazolinone DHQ derivative. With the usual caveats with regard to chirality, such compounds of this THIQ class are worthy development candidates for oncology.

Experimental Section {#sec4}
====================

Tubulin Assays {#sec4.1}
--------------

Bovine brain tubulin was prepared as previously described^[@ref31]^ and used in the studies presented. Assembly IC~50~'s were determined as fully described elsewhere.^[@ref32]^ In brief, 1.0 mg/mL (10 μM) tubulin was preincubated with varying compound concentrations without GTP for 15 min at 30 °C. Reaction mixtures were placed on ice, and GTP (final concentration, 0.4 mM) was added. Mixtures were transferred to cuvettes held at 0 °C in a recording spectrophotometer. Baselines were established at 0 °C and increase in turbidity was followed for 20 min following a rapid (\<30 s) jump to 30 °C. Concentrations of compound required to reduce the turbidity increase by 50% were determined. Inhibition of the binding of \[^3^H\]colchicine to tubulin was described fully previously.^[@ref33]^ Reaction mixtures contained 0.1 mg/mL (1.0 μM) tubulin, 5.0 μM \[^3^H\]colchicine, and a potential inhibitor at 5.0 μM. Compounds were compared to CA-4, a particularly potent inhibitor of colchicine binding to tubulin.^[@ref34]^ Mixtures were incubated for 10 min at 37 °C, a time point at which colchicine binding in control reaction mixtures is generally 40--60% complete.

Crystallization, Data Collection, and Structure Solution {#sec4.2}
--------------------------------------------------------

Crystals of T~2~R-TTL were generated as previously described.^[@ref25],[@ref35]^ Crystals were soaked for 3 h at 20 °C in a reservoir solution (10% PEG 4K, 16% glycerol, 30 mM MgCl~2~, 30 mM CaCl~2~, and 0.1 M 2-(*N*-morpholino)ethanesulfonic acid/imidazole pH 6.7) containing 5 mM of compound 10 (STX3451) and subsequently transferred into a reservoir supplemented with 20% glycerol before cryo-cooling in liquid nitrogen. All data were collected at the Swiss Light Source (beamline X06DA, Paul Scherrer Institut, Villingen PSI, Switzerland) with images indexed and processed using XDS.^[@ref36]^ Structure solution using the difference Fourier method and refinement were performed using PHENIX^[@ref37]^ and model building was carried out iteratively using Coot software.^[@ref38]^ The atomic coordinates and structure factors have been deposited in the Protein Data Bank ([www.rcsb.org](www.rcsb.org)) under accession number 6HX8 (T~2~R-TTL-STX3451).

Structural Analysis and Figure Preparation {#sec4.3}
------------------------------------------

Molecular graphics and analyses were carried out using PyMol (The PyMOL Molecular Graphics System, Version 1.8.6.2. Schrödinger, LLC).

Chemistry {#sec4.4}
---------

All chemicals were either purchased from Aldrich Chemical Co. (Gillingham, UK) or Alfa Aesar (Heysham, UK). Organic solvents of A.R. grade (PE, EtOAc, CHCl~3~, acetone, and CH~2~Cl~2~) were supplied by Fisher Scientific (Loughborough, UK) and were used as supplied. Petroleum ether (PE) used for crystallization was of fractions 40--60 °C. DMA and DMF were purchased from Aldrich and stored under a positive pressure of N~2~ after use. Sulfamoyl chloride was prepared using an adaptation of Appel and Berger methodology^[@ref39]^ and was stored in the refrigerator as a solution in toluene under a positive pressure of N~2~, as described by Woo et al.^[@ref40]^ An appropriate volume was freshly concentrated in vacuo immediately before use. Compound **9** was synthesized according to a literature procedure.^[@ref3]^ Reactions were performed at room temperature unless stated otherwise. Flash column chromatography was carried out on silica gel (MatrexC60). ^1^H NMR spectra were recorded with a Varian Mercury VX 400 NMR spectrometer and a Bruker AVIII HD 400 spectrometer at 400 MHz. ^13^C NMR spectra were recorded with a Bruker AVIII HD 400 spectrometer at 100 MHz. Chemical shifts are reported in parts per million (ppm) relative to the solvent residual peaks as internal standards. ^1^H NMR: 7.26 ppm (CDCl~3~); 2.05 ppm (acetone-d~6~). ^13^C NMR: 29.84 ppm (acetone-*d*~6~). High resolution mass spectrometry was performed using a Bruker microTOF electrospray ionization mass spectrometer. Compounds were ≥96% pure by reversed-phase HPLC run with CH~3~CN/H~2~O or MeOH/H~2~O (Sunfire C18 column, 4.6 × 150 mm, 3.5 μm pore size).

(±)-2-(2,3-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline **7a**. {#sec4.5}
----------------------------------------------------------------------------------------------

Compound **9** (386 mg, 2.0 mmol) was treated with 2,3-dichlorobenzyl bromide (506 mg, 2.1 mmol) and DIPEA (1.041 g, 8.0 mmol) in DMF (4.0 mL) at 140 °C for 18 h. After cooling to room temperature (RT), the reaction mixture was evaporated, then treated with H~2~O (100 mL) and NH~4~Cl (saturated, 10 mL) before extracting into EtOAc (2 × 100 mL). The combined organic layers were dried (NaCl), filtered, and evaporated. Purification by flash column chromatography (CHCl~3~/acetone 9:1 → 9:1 and 2% MeOH) afforded compound **7a** as a yellow solid (202 mg, 28%). ^1^H NMR (400 MHz, CDCl~3~): δ 1.14 (3H, d, *J* = 6.6), 2.52 (1H, dd, *J* = 16.1, 5.7), 2.94 (1H, dd, *J* = 15.9, 4.8), 3.14 (1H, sext, *J* 6.0), 3.56--3.90 (4H, m), 3.81 (3H, s), 5.42 (1H, s, br), 6.45 (1H, s), 6.66 (1H, s), 7.17 (1H, t, *J* 7.8), 7.35 (1H, dd, *J* 8.0, 1.3), and 7.50 (1H, d, *J* 7.0). LC/MS (ES^+^) *m*/*z*: 352.0 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 352.0872; C~18~H~20~Cl~2~NO~2~^+^, (M^+^ + H) requires 352.0866.

(±)-2-(2,4-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline **7b** {#sec4.6}
---------------------------------------------------------------------------------------------

Compound **9** (387 mg, 2.0 mmol), 2,4-dichlorobenzyl chloride (415 mg, 2.1 mmol), sodium bromide (41 mg, 0.4 mmol), and DIPEA (1.038 g, 8.0 mmol) in DMF (4.0 mL) were reacted at 140 °C for 18 h, as described for the synthesis of **7a**. Purification by flash column chromatography (CHCl~3~/acetone 9:1 → 9:1 and 2% MeOH) afforded compound **7b** as a yellow solid (341 mg, 48%). ^1^H NMR (400 MHz, CDCl~3~): δ 1.14 (3H, d, *J* = 6.5), 2.51 (1H, dd, *J* = 16.1, 5.8), 2.92 (1H, dd, *J* = 16.2, 4.8), 3.12 (1H, sext, *J* 6.1), 3.53--3.80 (4H, m), 3.81 (3H, s), 5.42 (1H, s, br), 6.44 (1H, s), 6.65 (1H, s), 7.21 (1H, dd, *J* = 8.3, 2.1), 7.36 (1H, d, *J* 2.1), and 7.51 (1H, d, *J* 8.3). LC/MS (ES+) *m*/*z*: 352.0 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 352.0869; C~18~H~20~Cl~2~NO~2~^+^, (M^+^ + H) requires 352.0866.

(±)-2-(2,5-Dichlorobenzyl)-6-hydroxy-7-methoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline **7c** {#sec4.7}
---------------------------------------------------------------------------------------------

Compound **9** (387 mg, 2.0 mmol), 2,5-dichlorobenzyl chloride (413 mg, 2.1 mmol), sodium bromide (41 mg, 0.4 mmol), and DIPEA (1.035 g, 8.0 mmol) in DMF (4.0 mL) were reacted at 140 °C for 18 h, as described for the synthesis of **7a**. Purification by flash column chromatography (CHCl~3~/acetone 9:1 → 9:1 and 2% MeOH) afforded compound **7c** as a yellow solid (275 mg, 39%). ^1^H NMR (400 MHz, CDCl~3~): δ 1.14 (3H, d, *J* = 6.6), 2.52 (1H, dd, *J* = 16.1, 5.9), 2.94 (1H, dd, *J* = 16.0, 5.0), 3.13 (1H, sext, *J* 6.1), 3.57--3.83 (4H, m), 3.82 (3H, s), 5.43 (1H, s, br), 6.46 (1H, s), 6.66 (1H, s), 7.14 (1H, dd, *J* = 8.5, 2.6), 7.26 (1H, d, *J* = 8.4), and 7.59 (1H, d, *J* = 2.5). LC/MS (ES^+^) *m*/*z*: 352.0 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 352.0875; C~18~H~20~Cl~2~NO~2~^+^, (M^+^ + H) requires 352.0866.

(±)-2-(2,3-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline **8a** {#sec4.8}
--------------------------------------------------------------------------------------------------

Sulfamoyl chloride (0.63 M in toluene, 2.4 mL, 1.5 mmol) was concentrated in vacuo and cooled to 0 °C until the reagent solidified. DMA (2.0 mL) was added, and the resulting solution was added directly to **7a** (176 mg, 0.5 mmol) at 0 °C. The reaction mixture was stirred at RT for 2 h. Sodium bicarbonate (saturated, 50 mL) was added, and the mixture was extracted with EtOAc (100 mL). The organic layer was washed repeatedly with water (8 × 100 mL), then brine (2 × 5 mL), and then dried (MgSO~4~) and evaporated. The residue was stirred in PE/CH~2~Cl~2~ (∼20 mL, ∼4:1) to afford compound **8a** as a pale yellow amorphous powder (150 mg, 69%). ^1^H NMR (400 MHz, acetone-*d*~6~): δ 1.17 (3H, d, *J* 6.5), 2.59 (1H, dd, *J* = 16.1, 5.5), 2.99 (1H, dd, *J* = 16.1, 5.1), 3.22 (1H, sext, *J* = 6.0), 3.67 (1H, d, *J* 16.0), 3.75 (1H, d, *J* 16.0), 3.78 (3H, s), 3.84 (1H, d, *J* = 14.6), 3.97 (1H, d, *J* = 14.6), 6.79 (1H, s), 6.90 (2H, s, br), 7.07 (1H, s), 7.35 (1H, t, *J* = 7.8), 7.50 (1H, dd, *J* = 8.0, 1.6), and 7.53 (1H, dd, *J* = 7.9, 1.6). ^13^C NMR (100 MHz, acetone-*d*~6~): δ 15.1 (CH~3~), 35.2 (CH~2~), 51.8 (CH~2~), 53.6 (CH), 55.6 (CH~2~), 56.2 (CH~3~), 111.7 (CH), 124.8 (CH), 126.6 (C), 128.5 (CH), 129.9 (CH), 130.1 (CH), 132.6 (C), 133.3 (C), 134.0 (C), 138.7 (C), 140.4 (C), and 151.1 (C). LC/MS (ES^+^) *m*/*z*: 431.1 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 431.0602; C~18~H~21~Cl~2~N~2~O~4~S^+^, (M^+^ + H) requires 431.0594.

(±)-2-(2,4-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline **8b** {#sec4.9}
--------------------------------------------------------------------------------------------------

The same method as for **8a** was followed using compound **7b** (317 mg, 0.9 mmol) and sulfamoyl chloride (0.63 M in toluene, 4.3 mL, 2.7 mmol) in DMA (3.6 mL) at RT for 2 h. The residue was stirred in PE/CH~2~Cl~2~ (∼20 mL, ∼4:1) to afford compound 8b as a pale yellow amorphous powder (240 mg, 61%). ^1^H NMR (400 MHz, acetone-*d*~*6*~): δ 1.15 (3H, d, *J* = 6.5), 2.57 (1H, dd, *J* = 16.1, 5.5), 2.97 (1H, dd, *J* = 16.1, 5.0), 3.17 (1H, sext, *J* = 6.0), 3.63 (1H, d, *J* = 16.0), 3.72 (1H, d, *J* = 16.0), 3.75 (1H, d, *J* = 14.5), 3.78 (3H, s), 3.90 (1H, d, *J* = 14.5), 6.79 (1H, s), 6.89 (2H, s, br), 7.06 (1H, s), 7.37 (1H, dd, *J* = 8.3, 2.2), 7.47 (1H, d, *J* = 2.2), and 7.63 (1H, d, *J* = 8.3). ^13^C NMR (100 MHz, acetone-*d*~6~): δ 15.1 (CH~3~), 35.3 (CH~2~), 51.8 (CH~2~), 53.4 (CH), 54.4 (CH~2~), 56.2 (CH~3~), 111.6 (CH), 124.8 (CH), 126.7 (C), 128.0 (CH), 129.7 (CH), 132.9 (CH), 133.5 (C), 134.2 (C), 135.4 (C), 137.0 (C), 138.6 (C), and 151.1 (C). LC/MS (ES^+^) *m*/*z*: 431.1 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 431.0599; C~18~H~21~Cl~2~N~2~O~4~S^+^, (M^+^ + H) requires 431.0594.

(±)-2-(2,5-Dichlorobenzyl)-7-methoxy-3-methyl-6-sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline **8c** {#sec4.10}
--------------------------------------------------------------------------------------------------

The same method as for **8a** was followed using compound **7c** (247 mg, 0.7 mmol) and sulfamoyl chloride (0.63 M in toluene, 3.4 mL, 2.1 mmol) in DMA (2.8 mL) at RT for 2 h. The residue was stirred in PE/CH~2~Cl~2~ (∼20 mL, ∼4:1) to afford compound 8c as a pale yellow amorphous powder (185 mg, 61%). ^1^H NMR (400 MHz, acetone-*d*~6~): δ 1.17 (3H, d, *J* = 6.5), 2.59 (1H, dd, *J* = 16.2, 5.6), 3.00 (1H, dd, *J* = 16.1, 4.9), 3.21 (1H, sext, *J* = 6.0), 3.68 (1H, *J* = 16.0), 3.76 (1H, *J* = 16.0), 3.78 (3H, s), 3.79 (1H, *J* = 15.0), 3.92 (1H, *J* = 15.0), 6.81 (1H, s), 6.90 (2H, s, br), 7.08 (1H, s), 7.32 (1H, dd, *J* = 8.5, 2.7), 7.43 (1H, d, *J* = 8.5), and 7.67 (1H, d, *J* = 2.7). ^13^C NMR (100 MHz, acetone-*d*~6~): δ 15.2 (CH~3~), 35.2 (CH~2~), 51.9 (CH~2~), 53.6 (CH), 54.6 (CH~2~), 56.2 (CH~3~), 111.7 (CH), 124.9 (CH), 126.6 (C), 129.1 (CH), 131.0 (CH), 131.7 (CH), 133.0 (C), 133.3 (C), 134.0 (C), 138.6 (C), 140.1 (C), and 151.1 (C). LC/MS (ES^+^) *m*/*z*: 431.1 (M^+^ + H). HRMS (ES^+^) *m*/*z*: found 431.0605; C~18~H~21~Cl~2~N~2~O~4~S^+^, (M^+^ + H) requires 431.0594.

^\#^ Biotrial, 35000 Rennes, France.

W.D. and A.E.P. contributed equally. All authors have given their approval to the final version of the manuscript.

The authors declare no competing financial interest.

The content of this paper is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.

The structure of **10** (STX3451) bound to the T~2~R-TTL complex has PDB access code 6HX8. Authors will release the atomic coordinates upon article publication

Synthetic work was supported by Sterix Ltd., a member of the Ipsen Group. We thank the NCI DTP for providing in vitro screening resources. X-Ray data were collected at the Swiss Light Source (beamline X06DA, Paul Scherrer Institut, Villigen PSI, Switzerland). This work was supported by a grant from the Swiss National Science Foundation (31003A_166608 to M.O.S.). We thank Dr M. P. Leese for early discussions.

THIQ

:   tetrahydroisoquinoline

2ME

:   2-methoxyestradiol

HUVEC

:   human umbilical vein endothelial cell

DHQ

:   dihydroquinazolinone

SAR

:   structure--activity relationship

DIPEA

:   diisopropylethylamine

DMF

:   *N*,*N*-dimethylformamide

DMA

:   *N*,*N*-dimethylacetamide

MGM

:   mean graph midpoint

GTP

:   guanosine 5′-triphosphate
